# Brimonidine 0.33% for Rosacea-Related Facial Erythema

> **NCT07431476** · PHASE4 · COMPLETED · sponsor: **Istanbul Training and Research Hospital** · enrollment: 45 (actual)

## Conditions studied

- Rosacea
- Rosacea Subtype 1 (Erythematotelangiectatic)

## Interventions

- **DRUG:** Brimonidine 0.33% gel
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT07431476
- **Lead sponsor:** Istanbul Training and Research Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-01
- **Primary completion:** 2025-08-07
- **Final completion:** 2025-08-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431476, "Brimonidine 0.33% for Rosacea-Related Facial Erythema". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07431476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*